Although randomized studies are lacking, in all studies in which ERα-negative breast cancer patients were treated with tamoxifen, the disease-free and overall survival was better in patients with high levels of retrospectively measured ERβ1 or ERβ-total expression compared to those with a low level of ERβ [61,62,63,64]. This evidence concerns the gene ESR1 and breast cancer.